两剂异源Ad26.ZEBOV、MVA-BN-Filo埃博拉疫苗在健康及HIV感染非洲成人中的安全性和免疫原性:一项随机安慰剂对照II期临床试验
该随机、观察者盲、安慰剂对照II期试验在非洲5个中心纳入668名健康成人和142名HIV感染成人,评估Ad26.ZEBOV初免后以28、56或84天间隔接种MVA-BN-Filo的安全性及免疫原性。结果显示疫苗耐受良好,无疫苗相关严重不良事件,最常见为注射部位疼痛及乏力、头痛、肌痛;56天间隔组抗体几何平均浓度高于28天组,抗体至少维持至1年,Ad26.ZEBOV加强接种可诱导回忆应答。
要点
- 两剂异源埃博拉疫苗在健康及HIV感染非洲成人中耐受良好,无疫苗相关严重不良事件。
- 将接种间隔从28天延长至56天可提高EBOV GP结合抗体几何平均浓度。
- 抗体应答至少维持至第365天,Ad26.ZEBOV加强接种可诱导回忆应答。
核心结论
- Ad26.ZEBOV、MVA-BN-Filo疫苗接种在健康及HIV感染非洲成人中耐受良好且具有免疫原性。
- 将接种间隔从28天延长至56天可改善体液免疫应答的幅度。
- 抗体水平至少维持1年,Ad26.ZEBOV加强接种显示存在疫苗诱导的免疫记忆。
研究设计与样本
- 随机、观察者盲、安慰剂对照II期临床试验,在肯尼亚1个中心及布基纳法索、科特迪瓦、乌干达各2个中心开展。
- 纳入668名18-70岁健康成人和142名18-50岁HIV感染成人,随机接受Ad26.ZEBOV后以28、56或84天间隔接种MVA-BN-Filo或生理盐水。
- 部分健康成人于第365天接受Ad26.ZEBOV或生理盐水加强接种。
- 主要终点为安全性,次要终点为免疫原性;不良事件收集至末次接种后42天,严重不良事件从签署知情同意书至研究结束。
主要发现
- 未观察到疫苗相关严重不良事件,不良事件主要为轻至中度;最常见 solicited 不良事件为注射部位疼痛(局部)及乏力、头痛、肌痛(全身)。
- HIV感染成人28天和56天间隔组几何平均浓度分别为4,207 EU/mL(95%CI 3,233-5,474)和5,283 EU/mL(95%CI 4,094-6,817)。
- 抗体应答观察到第365天;1年后Ad26.ZEBOV加强接种诱导回忆应答。
临床怎么用
- 在非洲健康及HIV感染成人中,两剂异源埃博拉疫苗方案可按56天间隔接种以提高抗体应答幅度。
- 接种后需关注注射部位疼痛及乏力、头痛、肌痛等常见不良事件,未观察到疫苗相关严重不良事件。
- 抗体至少维持1年,加强接种可诱导免疫记忆,支持免疫持久性评估。
局限性
- 部分健康成人未接种第二剂或未按方案定义间隔接种第二剂。
- 多数参与者随访时间限于365天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. METHODS AND FINDINGS: In this randomised, observer-blind, placebo-controlled Phase II trial, 668 healthy 18- to 70-year-olds and 142 HIV-infected 18- to 50-year-olds were enrolled from 1 site in Kenya and 2 sites each in Burkina Faso, Cote d'Ivoire, and Uganda. Participants received intramuscular Ad26.ZEBOV followed by MVA-BN-Filo at 28-, 56-, or 84-day intervals, or saline. Females represented 31.4% of the healthy adult cohort in contrast to 69.7% of the HIV-infected cohort. A subset of healthy adults received booster vaccination with Ad26.ZEBOV or saline at Day 365. Following vaccinations, adverse events (AEs) were collected until 42 days post last vaccination and serious AEs (SAEs) were recorded from signing of the ICF until the end of the study. The primary endpoint was safety, and the secondary endpoint was immunogenicity. Anti-Ebola virus glycoprotein (EBOV GP) binding and neutralising antibodies were measured at baseline and at predefined time points throughout the study. The first participant was enrolled on 9 November 2015, and the date of last participant's last visit was 12 February 2019. No vaccine-related SAEs and mainly mild-to-moderate AEs were observed among the participants. The most frequent solicited AEs were injection-site pain (local), and fatigue, headache, and myalgia (systemic), respectively. Twenty-one days post-MVA-BN-Filo vaccination, geometric mean concentrations (GMCs) with 95% confidence intervals (CIs) of EBOV GP binding antibodies in healthy adults in 28-, 56-, and 84-day interval groups were 3,085 EU/mL (2,648 to 3,594), 7,518 EU/mL (6,468 to 8,740), and 7,300 EU/mL (5,116 to 10,417), respectively. In HIV-infected adults in 28- and 56-day interval groups, GMCs were 4,207 EU/mL (3,233 to 5,474) and 5,283 EU/mL (4,094 to 6,817), respectively. Antibody responses were observed until Day 365. Ad26.ZEBOV booster vaccination after 1 year induced an anamnestic response. Study limitations include that some healthy adult participants either did not receive dose 2 or received dose 2 outside of their protocol-defined interval and that the follow-up period was limited to 365 days for most participants. CONCLUSIONS: Ad26.ZEBOV, MVA-BN-Filo vaccination was well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These data supported the approval by the European Union for prophylaxis against EBOV disease in adults and children ≥1 year of age. TRIAL REGISTRATION: ClinicalTrials.gov NCT02564523.
引用
- Barry H, Mutua G, Kibuuka H, et al. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 2021. PMID: 34714820. doi:10.1371/journal.pmed.1003813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。